8.00
+0.365(+4.78%)
Currency In USD
| Previous Close | 7.63 |
| Open | 7.58 |
| Day High | 8 |
| Day Low | 7.54 |
| 52-Week High | 17 |
| 52-Week Low | 4.92 |
| Volume | 651,784 |
| Average Volume | 781,120 |
| Market Cap | 615.73M |
| PE | -2.6 |
| EPS | -3.07 |
| Moving Average 50 Days | 11.1 |
| Moving Average 200 Days | 11.3 |
| Change | 0.37 |
If you invested $1000 in Replimune Group, Inc. (REPL) since IPO date, it would be worth $527.37 as of April 20, 2025 at a share price of $7.995. Whereas If you bought $1000 worth of Replimune Group, Inc. (REPL) shares 5 years ago, it would be worth $666.25 as of April 20, 2025 at a share price of $7.995.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Mar 07, 2025 9:01 PM GMT
WOBURN, Mass., March 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to n
Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma
GlobeNewswire Inc.
Jan 21, 2025 1:00 PM GMT
PDUFA action date of July 22, 2025, with priority reviewWOBURN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, tod
Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials
GlobeNewswire Inc.
Jan 08, 2025 1:00 PM GMT
WOBURN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the first patients have been enrolled
Data not available